Panitumumab superior to maintenance therapy alone for metastatic CRC
Click Here to Manage Email Alerts
Maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab better maintained wildtype metastatic colorectal cancer than 5-fluoruracil/leucovorin alone, according to data from a study presented at ASCO21.
“The combination of 5-fluoruracil/leucovorin [5FU/LV] plus panitumumab should be regarded as the preferred option of maintenance therapy following FOLFOX panitumumab in patients with RAS wild type metastatic colorectal cancer,” Dominik P. Modest, MD, of University Hospital of Munich in Germany, said.
Researchers observed tumor response over the course of maintenance therapy more frequently in patients receiving panitumumab arm, according to Modest.
The trial initiated with 387 patients and, ultimately, 265 patients were randomized into two groups. One group received maintenance therapy with panitumumab and one received maintenance therapy with 5FU/LV alone.
“The primary endpoint of the trial was progression-free survival, which was defined as time from randomization,” Modest said. “This is important [because] it was not inclusion but randomization; start of maintenance therapy to progression or death from any cause.”
Both subsets received six cycles of treatment with of 5FU/LV, FOLFOX and panitumumab prior to being randomized into the maintenance therapy groups.
“It is important to note that none of the analyzed subgroups trended towards better outcome with 5-fluoruracil/leucovorin alone,” Modest said.
Collapse
Modest, D, et all. Abstract 3503. Presented at: ASCO Annual Meeting 2021; June 4-8, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts